Randomized Trialhigh evidence
Clopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients.
The New England journal of medicine·August 29, 2026·PMID 42670964
Why it mattersFor high-ischemic-risk patients beyond 12 months after stenting, the trade-off between ischemic and bleeding risk with antiplatelet strategy is critical. This trial quantifies that trade-off, showing clopidogrel monotherapy reduces bleeding but increases ischemic events compared with extended DAPT, with no net clinical benefit.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled